Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2018 Sep 17;128(10):4743. doi: 10.1172/JCI124920

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Anna Sophia McKenney, Allison N Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T Rapaport, Minal A Patel, Efthymia Papalexi, Alan H Shih, April Chiu, Elizaveta Freinkman, Esra A Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok-Kin Wong, Raajit Rampal, Matthew G Vander Heiden, Craig B Thompson, Ross L Levine
PMCID: PMC6159958  PMID: 30222137

Original citation: J Clin Invest. 2018;128(2):789–804. https://doi.org/10.1172/JCI94516

Citation for this corrigendum: J Clin Invest. 2018;128(10):4743. https://doi.org/10.1172/JCI124920

Craig B. Thompson’s conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below.

CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

The authors regret the error.

Version 1. 09/17/2018

Electronic publication

Version 2. 10/01/2018

Print issue publication

Footnotes

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES